Content deleted Content added
180.252.21.114 (talk) No edit summary |
m Bot: Migrating 1 interwiki links, now provided by Wikidata on d:q4733443 |
||
Line 48: | Line 48: | ||
{{alkene-stub}} |
{{alkene-stub}} |
||
{{nervous-system-drug-stub}} |
{{nervous-system-drug-stub}} |
||
[[fa:آلیلگلیسین]] |
Revision as of 19:21, 19 March 2013
Names | |
---|---|
IUPAC name
2-Aminopent-4-enoic acid
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
ECHA InfoCard | 100.028.809 |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C5H9NO2 | |
Molar mass | 115.13 g/mol |
Appearance | white crystalline powder |
Density | 1.098 g/mL |
Melting point | 265 °C (509 °F; 538 K) |
Boiling point | 231 °C (448 °F; 504 K) |
Hazards | |
Occupational safety and health (OHS/OSH): | |
Main hazards
|
Irritant |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Allylglycine is a glycine derivative. It is an inhibitor of the enzyme glutamate decarboxylase.[1] Inhibition of glutamate decarboxylase blocks GABA biosynthesis, leading to lower levels of the neurotransmitter.[2] It is used to induce convulsions in animals in scientific studies.[citation needed]
References
- ^ Abshire VM, Hankins KD, Roehr KE, DiMicco JA (1988). "Injection of L-allylglycine into the posterior hypothalamus in rats causes decreases in local GABA which correlate with increases in heart rate". Neuropharmacology. 27 (11): 1171–7. doi:10.1016/0028-3908(88)90013-5. PMID 3205383.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Sajdyk T, Johnson P, Fitz S, Shekhar A (2008). "Chronic inhibition of GABA synthesis in the bed nucleus of the stria terminalis elicits anxiety-like behavior". J. Psychopharmacol. (Oxford). 22 (6): 633–41. doi:10.1177/0269881107082902. PMID 18308797.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link)